---
title: "Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296920200.md"
description: "The recent initiation of first patient dosing marks a significant advancement for IHL-42X, following promising Phase 2 RePOSA outcomes showing reductions in Apnea-Hypopnea Index (AHI) by as much as 83%. Additionally, the FDA has granted Fast Track designation to this innovative treatment. This achievement underscores the potential efficacy of IHL-42X in addressing sleep-related disorders and highlights its progress in clinical development."
datetime: "2026-08-25T12:47:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296920200.md)
  - [en](https://longbridge.com/en/news/296920200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296920200.md)
generator: "portal-rs"
---

# Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

The recent initiation of first patient dosing marks a significant advancement for IHL-42X, following promising Phase 2 RePOSA outcomes showing reductions in Apnea-Hypopnea Index (AHI) by as much as 83%. Additionally, the FDA has granted Fast Track designation to this innovative treatment. This achievement underscores the potential efficacy of IHL-42X in addressing sleep-related disorders and highlights its progress in clinical development.

### Related Stocks

- [IXHL.US](https://longbridge.com/en/quote/IXHL.US.md)

## Related News & Research

- [Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea](https://longbridge.com/en/news/293607970.md)
- [05:04 ETFor Pulmonary Fibrosis Awareness Month, American Lung Association Highlights Free Program to Help People Learn to Live With PF](https://longbridge.com/en/news/297625071.md)
- [Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands](https://longbridge.com/en/news/297404631.md)
- [Officials widen lettuce-linked cyclospora outbreak probe to 20 states](https://longbridge.com/en/news/297349147.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**